Wolfgang Miesbach on Insights from Guy Young’s ASH2025 Session on Next-Generation Gene Therapy
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared on LinkedIn:
”The Immunogenicity Challenge in Next-Generation Gene Therapy Dr. Guy Young‘s ASH2025 session “Deconstructing Gene Therapy in Haemophilia” highlighted a critical tension: the ASC618 Phase 1/2 trial shows both patients of the first cohort dosed with 2e12 vg/kg developed high-titer inhibitors to the ET3 transgene.
What is ASC618?
ASC618 uses ET3—a bioengineered BDD-FVIII chimera incorporating porcine sequences (A1/A3 domains) designed to enhance secretion 10–100x over native human FVIII, enabling lower doses.
The Problem:
These porcine residues could have acted as potent neo-antigens, breaking tolerance even in previously naive patients.
Both are now on emicizumab.
Predictive immunogenicity modeling for non-native constructs needs strengthening before clinical translation.”
All from ASH25 featured in Hemostasis Today.
-
Feb 2, 2026, 13:08Hammam Alminshawi: Time is Brain – Optimizing MRI for Acute Ischemic Stroke
-
Feb 2, 2026, 12:53Lucie Gelon: Proud to Share My 1st Achievements in The Scientific and Platelet World
-
Feb 2, 2026, 12:32Matthew Flick on SARS-CoV-2 Spike Protein and Coagulation Biology
-
Feb 2, 2026, 11:24Shivanand Kumatagi Delivers an Interactive Session on ISBT128 Standard
-
Feb 2, 2026, 11:03Meghan Delaney Congratulates Ruchika Goel for The Recent Paper on Pediatric Transfusion
-
Feb 2, 2026, 10:31Fayad Al-Haimus: Is Giving TXA Within “3 Hours” Really Enough?
-
Feb 2, 2026, 10:07David Benito Laorga’s Haemophilia Team Hosts Hemosfera
-
Feb 2, 2026, 09:49Tichakunda Mharazanye: A New Year, New Challenges, And New Milestones
-
Feb 2, 2026, 09:16Eyiuche Ezigbo Calls for Stronger VWD Awareness and Better Care in LMICs